Dova Pharmaceuticals Inc logo

DOVA - Dova Pharmaceuticals Inc News Story

$28.04 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £9.99m
Position in Universe th / 6841

BRIEF-Sobi To Acquire Dova Pharmaceuticals

Mon 30th September, 2019 7:49am
Sept 30 (Reuters) - Swedish Orphan Biovitrum  SOBIV.ST :
    * SOBI TO ACQUIRE DOVA PHARMACEUTICALS CREATING A GLOBAL
GROWTH
PLATFORM IN HAEMATOLOGY
    * CONSIDERATION CONSISTS OF AN UPFRONT PAYMENT OF USD 27.50
PER
SHARE IN CASH AND, ONE NON-TRADEABLE CONTINGENT VALUE RIGHT
(CVR)
    * CVR ENTITLES DOVA SHAREHOLDERS TO AN ADDITIONAL USD 1.50
PER
SHARE UPON APPROVAL OF DOPTELET® FOR USE IN CHEMOTHERAPY-INDUCED
THROMBOCYTOPENIA (CIT) BY US FOOD AND DRUG ADMINISTRATION (FDA)
    * UPFRONT CASH COMPONENT OF OFFER REPRESENTS A PREMIUM OF 36
PER
CENT BASED ON DOVA'S MOST RECENT CLOSING PRICE OF USD 20.19
    * DEAL FOR USD 915 MILLION
    * TRANSACTION IS VALUED AT UP TO USD 915 MILLION
(APPROXIMATELY
SEK 9.0 BILLION) ON A FULLY DILUTED BASIS.
    * TRANSACTION IS EXPECTED TO CLOSE IN Q4 2019
    * ACQUISITION OF DOVA WILL BE FINANCED BY A MIX OF EXISTING
CASH
RESOURCES AND DEBT COMPRISED OF NEW COMMITTED CREDIT FACILITIES
AS WELL AS SOBI'S EXISTING CREDIT FACILITIES

Source text for Eikon:  ID:nWkr5LzLqz 
Further company coverage:  SOBIV.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.